Back

Effect of empagliflozin versus placebo on body composition in patients with acute myocardial infarction and type 2 diabetes mellitus: subgroup analysis of the EMBODY trial

28 August 2020 (08:00 - 18:00)
Organised by:
Congress Presentation Part of: Risk Factors and Prevention ePosters Pharmacotherapy ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Yu Hoshika

Nippon Medical School Teaching Hospital, Tokyo (Japan)

217 More presentations in this session

Presentation thumbnail
The association between napping and the risk of cardiovascular disease and all-cause mortality: a systematic review and dose-response meta-analysis
Doctor Z. Pan (Guangzhou, CN)
Abstract Slides
Presentation thumbnail
Prediction of 10-year and lifetime risk of cancer in individual patients with established cardiovascular disease, results from UCC-SMART and CANTOS
Miss C. van 't Klooster (Utrecht, NL)
Abstract Slides
Presentation thumbnail
Geographical profiles of cardiovascular risk and the risk factors in China: data from a nationwide population-based screening project
Assistant Professor C. Wu (Beijing, CN)
Abstract Slides
Presentation thumbnail
Associations between life-course frailty and later-life heart size and function in the 1946 NSHD British birth cohort-an epidemiological study
Mr C. Topriceanu (London, GB)
Abstract Slides
Presentation thumbnail
Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction and estimating benefits from novel interventions
Doctor P. Welsh (Glasgow, GB)
Abstract Slides

Access the full session

Session thumbnail
Risk Factors and Prevention ePosters

The Event

Event poster

ESC Congress 2020

28 August 2020 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of dapagliflozin in non-diabetic patients with anterior wall ST-segment elevation acute myocardial infarction
15 March 2025
thumbnail
Congress Presentation
Body composition based on bioelectrical impedance analysis in patients after decompensated heart failure with sacubitril/valsartan therapy within 6 month of treatment
29 June 2021
thumbnail
Congress Presentation
Trace element equilibrium in acute heart failure and the effect of empagliflozin
20 May 2023
thumbnail
Congress Session
Future outlooks into heart failure management in the cardio-renal-metabolic syndrome
19 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources